signaling pathway. 8, 9 The majority of patients with FLT3 mutations have in-frame internal tandem duplications (ITD) of the juxtamembrane region of variable length, while a small portion has point mutations in the tyrosine kinase domain (TKD), typically D835Y. 8 The presence of FLT3 mutations, particularly ITD, has been shown to be a significant prognostic factor for lower remission rates and higher relapse rates, thereby reducing survival across all age groups. 10, 11 Chemotherapy has long been the mainstay of treatment for AML. 12 Induction therapy is typically initiated soon after diagnosis to achieve remission and is followed by consolidation and maintenance therapy in an effort to maintain remission and eradicate residual malignant disease. 12 In case of relapse after initial complete remission, a second remission can sometimes be induced with additional chemotherapy. Hematopoietic stem cell transplantation (HSCT) is often used in patients in first remission who are at high risk of relapse (defined based on poor prognostic factors, such as the presence of FLT3 mutations), or in patients in second remission. 12, 13 Overall cure rates following chemotherapy with or without HSCT are only 35%-40% in patients under age 60 and 5%-15% in patients over age 60.
14 These low cure rates have prompted the development of targeted therapies, including those with activity against FLT3 mutations. 8 First-generation FLT3 inhibitors are multi-target tyrosine kinase inhibitors 8 and midostaurin is currently the only one approved for the treatment, in combination with standard cytarabine-based chemotherapy, for newly diagnosed FLT3-mutated AML (FLT3 mut AML) in the United States, 15 Canada, 16 and
Europe. 17 Second-generation FLT3 inhibitors have higher specificity for FLT3 8 and a number of them are being evaluated in latephase clinical trials or are under FDA review, including gilteritinib, crenolanib, and quizartinib. 8, 18 The introduction of new treatment options are likely to have an impact on treatment patterns that therefore need to be characterized. However, while real-world treatment patterns among patients with AML have been assessed in some claims data studies, these studies mostly focused on elderly patients in the United States and did not differentiate between patients with FLT3 mut AML and FLT3 wild-type AML (FLT3 wt AML). 19, 20 The evolving AML treatment landscape is also likely to change how healthcare resources are utilized in clinical practice. Previous studies have shown that the clinical management of AML is very resource intensive, as evidenced by elevated treatment costs largely driven by hospitalizations. 23, 24 However, these studies are mainly based on administrative claims data, which do not include FLT3 mutation status, and are mostly from the United States, thus not providing a more global perspective.
To provide a more comprehensive and timely overview of how currently available treatments for FLT3 mut AML and healthcare resources are used in clinical practice around the world, this study used medical chart data from 10 countries to assess real-world treatment patterns and AML-related healthcare resource utilization (HRU) among patients with FLT3 mut and FLT3 wt AML stratified by age and disease status. Eligible patients were randomly selected by the physicians based on the inclusion criteria detailed below. Physicians were asked to extract medical chart data from eligible patients into an electronic case report form, which had been pilot-tested with hematologists and oncologists to ensure clarity of the questions. To ensure a uniform sample size across cohorts (defined below), invitations to participate were staggered over time so that those sent at a later time could limit physicians to abstract data from patients in the cohorts with smaller sample sizes.
| PATIENTS AND ME THODS

| Data source
Patient data were anonymous and non-identifiable. Exemption from full review by the institutional review board was granted by the New England Institutional Review Board.
| Inclusion criteria
Patients were considered eligible for inclusion if: they had a new (ND) or relapsed/refractory (R/R) diagnosis of AML but not acute promyelocytic leukemia (APL); were at least 18 years old at the time of the AML diagnosis; had a known FLT3 mutation status; were under the care of the participating physician from the initial AML diagnosis; and had available AML-related patient medical records, including treatments and hospitalizations.
| Study design and cohorts
For ND AML patients, the index date was defined as the date of first treatment after the initial AML diagnosis, between 2013 and 2015. For R/R AML patients, the index date was defined as the date of first relapse after the initial treatment or of being refractory to the initial treatment, between 2013 and 2015. For all patients, the baseline period was defined as the period from the date of the initial AML diagnosis to the index date, while the study period was defined as the period from the index date to the last follow-up or death ( Figure 1 ). To assess treatment patterns, treatment information was collected for the first three lines of therapy after the index date.
| Study outcomes and statistical analyses
Therapies were classified using the following hierarchical order: (a) In addition to the above therapies, information on HSCT (including allogeneic, reduced-intensity allogeneic, and autologous HSCT) was collected and summarized.
To evaluate adherence to treatment guidelines in clinical practice, the treatment regimens recommended by the National
Comprehensive Cancer Network (NCCN) guidelines for the treatment of AML 26 were compared to those observed in this study.
Although the AML patients included in this study were not only from the United States, the comparison was conducted with the NCCN guidelines. 26 This was because the NCCN guidelines provide the most detail about specific regimens and are similar to the guidelines used in the other countries, including the European Society for Medical Oncology (ESMO), 27 Japanese Society of Hematology (JSH), 28 and European LeukemiaNet (ELN) guidelines. 29 More specifically, the therapies recommended in the NCCN guidelines 26 for per month. In all the analyses, continuous variables were summarized using means, standard deviations (SD), and medians, while categorical variables were summarized using counts and proportions.
All analyses were summarized descriptively without any statistical inferences made between cohorts.
| RE SULTS
| Patient and disease characteristics
The medical records of 1,027 AML patients were abstracted by 385 hematologists and oncologists from the 10 countries included in the study. Of these patients, 183 were assigned to the FLT3 Patients with ND AML had a median time from the initial AML diagnosis to initiation of the first treatment ranging from 0.3 to 0.8 months across cohorts. R/R AML patients had a median time from the initial AML diagnosis to the time of being classified as R/R that ranged from 8.1 to 8.8 months across cohorts.
| Treatment patterns
Among ND patients aged 18-64 years with FLT3 mut and FLT3 wt AML, the two most common initial treatments were SDAC-based therapies (43.2% and 55.9%, respectively) and HMA-based therapies (13.7% and 11.8%, respectively) ( TA 
| Healthcare resource utilization
In the overall patient sample, monthly AML-related HRU measures (inpatient admissions, inpatient days, ICU days, outpatient visits, ED visits, blood transfusions, and antibiotic treatment courses) were greater during the post-event period compared with the event-free period, with the exception of outpatient visits 
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TA B L E 3 Patterns of initial AML therapies and stem cell transplantation by cohort (Table S2) .
At the cohort level, monthly AML-related hospitalizations, ICU visits, and ED visits are generally greater during the post-event period compared with the event-free period. Outpatient visits were more frequent during the event-free period than during the postevent period for R/R AML patients (8.5 vs 7.2), but were similar for ND AML patients (6.9 vs 7.1 for the 18-64 age range; 7.0 vs 7.3 for the ≥65 age range) ( Figure S1 ). Moreover, in both the event-free and the post-event periods, fewer inpatient admissions were observed for ND AML patients who were 18-64 years old compared with ND AML patients who were ≥65 years old and all patients with R/R AML. On the other hand, ND AML patients who were 18-64 years old had more ICU days, blood transfusions, and antibiotic treatments compared with all other patients in both the event-free and postevent periods ( Figure S1 ). The range of observed values in individual HRU measures was large among patients across all cohorts.
| D ISCUSS I ON
This study sought to assess real-world treatment patterns and HRU among adult patients with FLT3 mut and FLT3 wt AML. Importantly, the study population included patient charts from 10 different countries, providing a global perspective of how patients with AML are treated and healthcare resources utilized in the real world.
The results of this study showed that treatment patterns were heterogeneous across cohorts, with many different treatment regimens observed within each cohort. In ND patients, the treatment for FLT3 mut AML tended to be more aggressive than that for FLT3 wt AML across cohorts, consistent with the poorer prognosis associated with FLT3 mutations. 10, 11, 30 Substantial HRU was observed across cohorts, and patients who were older or had R/R AML had more AML-related hospitalizations than younger ND patients; some of these HRU items are often associated with significant medical costs-eg, hospitalizations (especially ones that involve ICU stays) and blood transfusion. 23, 25, 31, 32 Overall, all HRU measures except outpatient visits showed an increase after the occurrence of a relapse or treatment failure, most likely due to hospitalizations or the initiation of additional treatments.
The heterogeneity of treatment patterns and large variations in HRU across and within cohorts may be due to differences in patient populations, clinical practices, and treatment availability across countries. As new FLT3-targeted therapies are approved around the world, treatment patterns and HRU among patients with FLT3 mut AML are likely to evolve. In the present study, the first-generation FLT3 inhibitor midostaurin was found to be rarely used across cohorts. Since midostaurin was approved after the data used in this study were collected, it is likely that the rare in- The event-free period was defined as the period free of relapses for the four ND cohorts, and the period before the next relapse or treatment failure for the two R/R cohorts.
2 The post-event period was defined as the period after the occurrence of a relapse or treatment failure after the index date placebo + induction chemotherapy). 33 In addition, while efficacy data from Phase 3 trials of second-generation FLT3 inhibitors in ND FLT3 mut AML patients are not yet available, data from Phase 1 or 2 trials suggest a significant response rate in R/R FLT3 mut AML patients. 34, 35 As a result of the evolving treatment landscape for AML, along with increased testing for genetic mutations, treatment guidelines are likely to undergo changes, further promoting a wider use of FLT3 inhibitors in clinical practice. In the present study, the treatments most commonly used by ND AML patients were found to be consistent with the NCCN guidelines, 26 but a considerable proportion of patients received non-recommended combination treatments.
A lack of standardization of treatment has also been reported in other studies regarding treatment decisions for elderly patients with AML. 19, 20 Additionally, these studies made the argument that palliative care is used too frequently among older patients without considering the tolerability of intensive treatments and weighing factors such as age, genetic and cytogenetic profiles, and overall health. Intensive induction therapies tend to be more commonly used in younger patients, [20] [21] [22] consistent with the finding of this study that only approximately 40% of patients aged 65 years or older received first-line SDAC or HDAC. Despite receiving less intensive therapy, older patients have been reported to have more inpatient admissions. [20] [21] [22] In one US study, 77.0% of Medicare beneficiaries had 0.63 AML-related inpatient visits per month and 6.63 AML-related inpatient days per month, in the same range as the estimates reported in the current study. 22 More transfusions per month have also been reported in older AML patients. 20 Despite differences in patient populations, study designs, and methodologies, all these studies point to substantial HRU among patients with AML, especially, as found in this study, in the presence of FLT3 mutations and after a relapse or treatment failure.
Overall, the heterogeneity of treatment patterns reported in this study suggests the need for more effective and standardized treatment strategies and better-defined treatment guidelines for AML patients, particularly those harboring FLT3 mutations. As secondgeneration FLT3 inhibitors are approved and existing first-generation inhibitors become more widely used in clinical practice, further studies are warranted to assess any changes in treatment patterns and HRU over time.
The results of this study should be interpreted in light of some limitations. First, the results may not be generalizable to patients from countries not included in this study as the standard of care and clinical practices may differ. Second, the US-based NCCN guidelines 26 were used as the treatment pattern benchmark to assess adherence to guidelines even though the study sample comprised patient data from different countries. While the NCCN guidelines 26 are similar to those from other countries, some differences exist and these should be taken into consideration when interpreting the results of this study. Lastly, as with any retrospective observational study, there is the potential for missing or inaccurate data recorded in the medical charts or for errors introduced during data entry.
| CON CLUS IONS
This study found considerable heterogeneity in 
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